Stocks making the biggest moves premarket: Constellation Energy, Option Care Health, Lennar, P&G and more

Constellation Energy rose more than 6% after Google agreed to buy power tied to 890 MW of new nuclear capacity and a separate 2,700-MW supply agreement, supporting more than $4.3 billion of Constellation investment; Option Care Health surged more than 20% on a report that McKesson and Clayton Dubilier & Rice are in advanced talks to acquire it for more than $5 billion. NeoGenomics rose 5% after reporting preliminary third-quarter revenue of $209 million versus a $205.9 million consensus and naming Warren Stone as CEO starting January 2027. AMD, Procter & Gamble and Corteva also gained after analyst target increases or upgrades; Berkshire Hathaway disclosed buying about 2.4 million Lennar shares.

Analysis

The clearest second-order signal is that large AI buyers may be underwriting long-duration, firm power—not just near-term renewable certificates. That strengthens the strategic value of existing nuclear generation and could improve bargaining power for other dispatchable suppliers, but CEG’s upside depends on contract economics, delivery milestones, and whether new capacity earns returns above its financing and construction costs. The announcement is not evidence that the full investment is already committed or risk-free; verify the agreement’s pricing, cost allocation, and regulatory path before extrapolating to earnings.

AMD’s CPU narrative is plausible if agent workloads add sustained inference, orchestration, and server-side compute. It is not yet proof of incremental AMD revenue: workload mix, customer deployment timing, and competition from GPUs and other CPU vendors determine the conversion. Treat the broker target as sentiment, not a fundamental catalyst.

OPCH’s reported process creates binary event risk after a sharp repricing. Without terms or confirmation, buyers face deal-break risk; MCK holders face capital-allocation and integration risk if a transaction advances. NEO’s preliminary beat may support estimates near term, but the CEO transition is distant and the revenue datapoint alone says little about margins. For CTVA, verify the cited target and reference price: the stated upside appears unusually large, making source/date consistency a prerequisite, not a thesis. Overall, the news flow is positive but uneven; avoid treating analyst upgrades as independent earnings evidence.

Key Decisions for Investors

• CEG: Do not chase the opening gap. Consider a staged long only after reviewing contract pricing, capex commitments, and regulatory milestones; thesis is falsified by material cost overruns, delayed approvals, or economics that fail to cover financing costs. Near-term catalyst is contract disclosure; structural payoff, if any, is years out.
• AMD: Keep any long exposure small and add only on evidence of CPU-driven revenue or guidance improvement over the next 1–3 quarters. Monitor server CPU mix and customer deployment commentary; reduce exposure if AI spending remains GPU-centric or AMD’s data-center growth fails to reflect the claimed workload shift.
• OPCH/MCK: Avoid event-driven entry in OPCH until a signed proposal, financing, and transaction terms are disclosed. If talks fail, the premium can unwind; if they proceed, assess MCK’s funding and integration burden rather than assuming the deal is automatically accretive.
• CTVA: Place on watch, not a target-driven buy, until JPMorgan’s target date, reference price, and assumptions are confirmed. The thesis needs improving crop-chemical demand/pricing and supportive farm economics; weaker commodity prices or channel inventory would undermine it.